Vir Biotechnology Inc. (VIR) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 2, 2023 4:05 PM EDTCompany to present new data at AASLD from Phase 2 chronic hepatitis B and chronic hepatitis delta clinical trials
Company expanding strategic focus to autoimmune diseases and immuno-oncology
Jennifer Towne, Ph.D., appointed as Executive Vice President and Chief Scientific Officer, effective November 6, 2023
Secured new BARDA funding for the development of RNA-delivered monoclonal antibodies
$1.7 billion in cash, cash equivalents and investments as of September 30, 2023
Conference call scheduled for 1:30 p.m. PT / 4:30 p.m. ET, November 2, 2023
SAN FRANCISCO--(BUSINESS WIRE)-- Vir... More
